Tocqueville Asset Management L.P. Seelos Therapeutics, Inc. Transaction History

Tocqueville Asset Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.66 - $1.22 $6,600 - $12,200	-10,000 Reduced 17.24%	48,000 $57,000
Q1 2023 May 10, 2023	BUY	$0.59 - $1.04 $1,770 - $3,120	3,000 Added 5.45%	58,000 $40,000
Q3 2022 Nov 10, 2022	SELL	$0.65 - $278.68 $41,210 - $17.7 Million	-63,400 Reduced 53.55%	55,000 $57,000
Q4 2021 Feb 14, 2022	SELL	$1.59 - $2.38 $8,745 - $13,090	-5,500 Reduced 4.44%	118,400 $193,000
Q3 2021 Nov 15, 2021	SELL	$1.69 - $2.89 $59,150 - $101,150	-35,000 Reduced 22.03%	123,900 $299,000
Q2 2021 Aug 16, 2021	SELL	$2.64 - $6.32 $105,336 - $252,168	-39,900 Reduced 20.07%	158,900 $419,000
Q1 2021 May 17, 2021	BUY	$1.35 - $4.99 $126,630 - $468,062	93,800 Added 89.33%	198,800 $992,000
Q4 2020 Feb 16, 2021	BUY	$0.74 - $2.01 $48,100 - $130,649	65,000 Added 162.5%	105,000 $166,000
Q3 2020 Nov 16, 2020	SELL	$0.6 - $1.25 $84,900 - $176,875	-141,500 Reduced 77.96%	40,000 $37,000
Q2 2020 Aug 12, 2020	SELL	$0.42 - $1.51 $3,990 - $14,345	-9,500 Reduced 4.97%	181,500 $183,000
Q1 2020 May 15, 2020	BUY	$0.47 - $1.56 $89,770 - $297,960	191,000 New	191,000 $94,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $341M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.